PROMPT:

Write a concise summary of the following:


REPORTING.The 15 Secretary may, for each rebatable covered part D 16 drug, delay the timeframe for reporting the informa17 tion and rebate amount described in subparagraphs 18 (A) and (B) of such paragraph for the applicable pe19 riods beginning October 1, 2022, and October 1, 2023, 20 until not later than December 31, 2025. 21 (b) REBATE AMOUNT. 22 (1) IN GENERAL. 23 (A) CALCULATION.For purposes of this 24 section, the amount specified in this subsection 25 for a dosage form and strength with respect to a 146  HR 5376 EAS 1 part D rebatable drug and applicable period is, 2 subject to subparagraph (C), paragraph (5)(B), 3 and paragraph (6), the estimated amount equal 4 to the product of 5 (i) subject to subparagraph (B) of this 6 paragraph, the total number of units of 7 such dosage form and strength for each 8 rebatable covered part D drug dispensed 9 under this part during the applicable pe10 riod; and 11 (ii) the amount (if any) by which 12 (I) the annual manufacturer 13 price (as determined in paragraph (2)) 14 paid for such dosage form and strength 15 with respect to such part D rebatable 16 drug for the period; exceeds 17 (II) the inflation-adjusted pay18 ment amount determined under para19 graph (3) for such dosage form and 20 strength with respect to such part D 21 rebatable drug for the period. 22 (B) EXCLUDED UNITS.For purposes of 23 subparagraph (A)(i), beginning with plan year 24 2026, the Secretary shall exclude from the total 25 number of units for a dosage form and strength 147  HR 5376 EAS 1 with respect to a part D rebatable drug, with re2 spect to an applicable period, units of each dos3 age form and strength of such part D rebatable 4 drug for which the manufacturer provides a dis5 count under the program under section 340B of 6 the Public Health Service Act. 7 (C) REDUCTION OR WAIVER FOR SHORT8 AGES AND SEVERE SUPPLY CHAIN DISRUP9 TIONS.The Secretary shall reduce or waive the 10 amount under subparagraph (A) with


CONCISE SUMMARY:

==========

RESPONSE:

The 15 Secretary may, for each rebatable covered part D 16 drug, delay the timeframe for reporting the informa17 tion and rebate amount described in subparagraphs 18 (A) and (B) of such paragraph for the applicable pe19 riods beginning October 1, 2022, and October 1, 2023, 20 until not later than December 31, 2025. 21 (b) REBATE AMOUNT. 22 (1) IN GENERAL. 23 (A) CALCULATION.For purposes of this 24 section, the amount specified in this subsection 25 for a dosage form and strength with respect to a part D rebatable drug and applicable period is, subject to subparagraph (C), paragraph (5)(B), and paragraph (6), the estimated amount equal to the product of (i) subject to subparagraph (B) of this paragraph, the total number of units of such dosage form and strength for each rebatable covered part D drug dispensed under this part during the applicable period; and (ii) the amount (if any) by which (I) the annual manufacturer price (as determined in paragraph (2)) paid for such dosage form and strength with respect to such part D rebatable drug for the period; exceeds (II) the inflation-adjusted payment amount determined under paragraph (3) for such dosage form and strength with respect to such part D rebatable drug for the period. (B) EXCLUDED UNITS.For purposes of subparagraph (A)(i), beginning with plan year 2026, the Secretary shall exclude from the total number of units for a dosage form and strength with respect to a part D rebatable drug, with respect to an applicable period, units of each dosage form and strength of such part D rebatable drug for which the manufacturer provides a discount under the program under section 340B of the Public Health Service Act. (C) REDUCTION OR WAIVER FOR SHORTAGES AND SEVERE SUPPLY CHAIN DISRUPTIONS.The Secretary shall reduce or waive the amount under subparagraph (A) with